Core Insights - Northern Trust Corporation (NTRS) successfully passed the Federal Reserve's 2025 stress test, maintaining a 2.5% Stress Capital Buffer, indicating a strong capital position and resilience against severe economic downturns [1][3] - Analysts have revised earnings growth estimates for NTRS upward for 2024 and 2025, reflecting optimism about the company's financial performance [2] Financial Performance - The Zacks Consensus Estimate for NTRS's earnings per share (EPS) for 2025 is projected at $8.18, with a year-over-year growth estimate of 6.23% [12] - Over the past three to five years, NTRS's EPS has increased by 3.1%, with a projected growth rate of 6.2% in the near term [8][11] - The company reported a return on equity (ROE) of 13% in the first quarter of 2025, indicating consistent profitability and operational efficiency [16] Dividend and Share Repurchase - Following the stress test, NTRS plans to increase its quarterly dividend by 7% to $0.80 per share starting in Q3 2025, subject to board approval, with a current dividend yield of 2.34% [4] - NTRS has an active share repurchase program, having repurchased $287 million worth of shares in Q1 2025, with $25 million authorized for buybacks [6] Growth Drivers - The company has experienced a compound annual growth rate (CAGR) of 7.8% in total revenues from 2020 to 2024, supported by increases in net interest income (NII) and non-interest income [12][14] - Loan and lease balances grew at a CAGR of 6.7% during the same period, with expectations for a rebound in loan activity as the client base expands [13][14] - The launch of Family Office Solutions in April 2025 aims to attract ultra-high-net-worth clients, enhancing revenue potential [14] Cost Management - Northern Trust is implementing cost optimization measures, including disciplined headcount management and process automation, to enhance productivity and achieve financial objectives [15] - The company has maintained a solid liquidity position, with deposits totaling $52 billion compared to total debt of $12 billion, supporting its financial flexibility [7] Market Performance - Over the past year, NTRS shares have increased by 53.1%, outperforming the industry growth of 28.6% [17] - NTRS currently holds a Zacks Rank of 2 (Buy), indicating positive market sentiment [20]

A vegan-leather start up is slated to tap the municipal bond market this week, marking a test of investor confidence in speculative project finance https://t.co/kztm8pk1wP ...

Key Takeaways COF will wind down Discover's home equity and refinance loan business following a strategic review. Originations will stop, but COF will keep servicing existing loans and explore sale options. Most staff will stay to support the transition, though some job cuts may occur during the wind-down process.Capital One Financial Corporation (COF) has decided to wind down the home equity lending business it acquired while buying Discover Financial in May. The news was first reported by Banking Dive.A ...

[Music] When I was scrolling through YouTube one day, I stumbled upon a video that horrified me. It was a rabbit wearing makeup. It was wearing lipstick.Hi, my name is Kira Wong Chu from Ya Guangjo School. I have a deep love for animals and today I hope to inspire all of you to stop the cruelty of animal testing. I was horrified to learn that humans test products on animals like creams, cosmetics, makeup, and medication on innocent animals such as mice and rabbits.The injuries they get are skin irritation, ...

“The gangs basically ended up taking over.”@fsimcilwraith tells “The Intelligence” how Latin America’s mining operations have been infiltrated, with violent results https://t.co/O3pHHeOPuc https://t.co/Za29FVF5hO ...

美国银行表示，新任首席执行官Antonio Filosa自6月23日上任以来，面临诸多难题。美国市场方面，销 量仍然低迷，美国自4月份以来对墨西哥进口产品(占Stellantis美国销量的40%)征收关税，而定价必须与 同行(通用/福特)保持一致，以防止市场份额下降，但新车型在2026财年(最早在2025年第四季度)才真正 产生影响。欧洲市场方面，由于二氧化碳排放法规，Stellantis需要推动纯电动汽车的销售，而车型发布 陷入停滞。此外，Stellantis的业绩恐疲软，美银预计上半年经调整税前利润为25亿欧元，较市场预期低 15%，2025财年和2026财年的税前利润预估也低于市场普遍预期。Stellantis业绩改善还需要一段时间， 2025财年是一个过渡期。 积极的一面是，Stellantis盈利有望再次回升，战略选择有助于支撑估值。美国银行认为，Stellantis股价 几乎没有下行空间，因为在美国市场的推动下，该公司的盈利应该会在2026财年大幅回升。美国银行预 计2026财年美国营收将同比增长13%，进而推动盈利回升。这主要得益于Jeep和RAM的新车型发布，但 该公司如何应对关税仍有待观察。 ...

Vancouver, British Columbia--(Newsfile Corp. - July 8, 2025) - Starcore International Mines Ltd. (TSX: SAM) ("Starcore" or the "Company") announces its intention to spin out its exploration interests in various permit and permit applications in a highly prospective region of Cote d'Ivoire, West Africa. Through its wholly-owned subsidiary, Starcore currently has interests over land holdings covering an aggregate area of 1,393 km2 which includes the exploration permit granted to its Kimoukro Gold Project.Sta ...

If we don't believe in a correction where people feel heard, where differences can exist again in the way they they used to. And it's not that those times were great in other ways. Those times were not great in other ways.But there was a kind of civility. There was a kind of elegance to our differences. There was a kind of nobility to office. There was a grace. There was a love for diplomacy.We understood government in a different way. I think we used to appreciate civics more and I feel like all of that is ...

July 3, 2025 11:26 AM GMT Infineon Technologies AG | Europe TSMC to exit GaN/Silicon Key Takeaways What has happened? Navitas recently announced that TSMC will end GaN/Si production in July 2027, suggesting the foundry player is set to wind down some non-core capabilities, especially where the pressures of competing with lower-cost Chinese manufacturing are evident, as with GaN/Si wafers. TSMC's strategic exit from GaN production is prompting Navitas (covered by our US colleague Joe Moore) to diversify its ...

Financial Highlights - Eledon had $1402 million in cash, cash equivalents, and short-term investments as of December 31, 2024[6] - The company forecasts sufficient funds to support operations through the end of 2026[6] Tegoprubart Clinical Development - The Phase 2 BESTOW trial of tegoprubart in kidney transplantation has completed enrollment, with top-line data expected in 4Q 2025[8] - Interim data update from the investigator-sponsored Phase 2 trial in islet cell transplantation for Type 1 diabetes is expected in Q4 2025[8] - A Phase 1b kidney transplant trial is ongoing, with an interim data update expected in mid-2025[8] Kidney Transplantation Market - The U S Medicare expenditure for end-stage renal disease and transplant is $50+ billion annually, including kidney transplantation costs of $440,000+ per transplant[23] - The global organ transplant immunosuppressant market size is estimated at $53+ billion[23] - Approximately 60% of organ transplants in the U S are kidney transplants[15] - Over 30-50% of kidney transplants fail within 10 years on the current standard of care immunosuppression[25] Islet Cell Transplantation - Approximately 2 million Americans live with Type 1 diabetes (T1D)[58] - Around 12% of people with T1D experience recurrent severe hypoglycemic events annually[58]